Marc Evanchik, M.S.

Marc Evanchik is Chief Scientific Officer at Braveheart Bio where he leads scientific strategy, spanning target discovery through late-stage development.

With more than 25 years in the biotech industry, Marc brings deep expertise in the discovery and development of novel medicines and cardiac myosin inhibitors in particular. Prior to joining Braveheart, Marc played a key role in establishing pharmacology capabilities at MyoKardia and led cardiovascular research atEdgewise Therapeutics. Over the course of his career, Marc moved multiple therapeutic candidates into registrational studies and was instrumental in advancing the development of Camzyos® (mavacamten), the first-in-class cardiac myosin inhibitor.

Marc is also an inventor on multiple patents related to novel treatments for heart muscle disorders and cardiac remodeling. He has a B.S. in Chemistry from the University of California, Santa Cruz, and an M.S. in Chemistry from the University of California, Davis.

‍